Magia - COSME Cluster Go international project - 2018-2020
BioWin is member of COSME Cluster Go international project "Magia" in the medical technologies sector (MedTech) i.e. medical devices, In Vitro Diagnostics and medical imaging equipment. The initiative shall support MedTech sector especially SMEs and business network organisations to intensify collaboration across borders with four industrial clusters: Bioindustry Silvano Fumero (Italy), BioWin (Belgium), Lyonbiopole (France) and Norgenta Nordeutsche (Germany). The ultimate goal of the project is to develop and implement joint strategies to strengthen, through cooperation and resource-sharing, the competitiveness on 2 target global markets of clusters’ SMEs operating in the field and to make the innovative European medtech industry more visible.
ABC Europe (CIP – Europe Innova - DG Entreprise) - 2009-2012
This project is essentially aimed at promoting transnational cooperation between European Health clusters to develop and implement useful tools to increase the international dimension of the clusters and their SME members.It brings together 13 Health clusters : Milan Chamber of Commerce and Industry (IT – Coordinator) – One Nucleus (GB) – Stockholm Science City (SE) – Medicon Valley Alliance (DK-SE) – BioWin (BE) – Medicen (FR) – Alsace Biovalley (FR) - Heidelberg (DE) – BioM (DE)- Cluster BioPMed (IT) – Innova (HU) – El Parc Cientific de Barcelona (SP) – Matimop (IS).
Tissue Engineering and Regenerative Medicine – TERM (Regions of Knowledge – DG Research) - 2010-2013
The “Regions of Knowledge” projects specifically bring together “triple helix” clusters, that is clusters driven by a culture of applied innovation through partnerships between industries and university and non-university research centres and supported by their regional authorities. Clusters and public authorities play an active role in the project to ensure that it is a priority for the region.
The initial aim of TERM is to establish a consensus between 13 partners from 7 European regions about a research agenda and non-R&D priorities in the field of regenerative medicine. The partners will then implement these priorities by means of tools that they will develop together (action plan). Partners: Atlanpole Biothérapies (FR - Coordinator) - MedCoast Scandinavia (NO/SE) - Fondazione Centro San Raffaele del Monte Tabor (IT) - UppsalaBIO (SE) - BioWin (BE) - Madrid BioCluster (ES) - Baltic Innovation Agency (EE) - Berlin – Brandenburg Centre for Regenerative Therapies (DE) - Interface Europe (BE) - Région Pays de la Loire (FR) - Service public de Wallonie (BE) - Vinnova (SE) - Uppsala Regional Council (SE).
Nanocardio - INTERREG project - 2016 to 2020
Nanocardio project aims to develop systems for the early diagnosis of atherosclerosis and the risks resulting from it. The project is based on the development of nanoplatforms carrying magnetic and optical diagnostic probes, respectively for magnetic resonance imaging (MRI) and optical imaging (fluorescence). These nanoplatforms will also have a specific system for the recognition of cells from atheromatous plaques. The objective, therefore, is the early detection of atheromatous plaques in order to evaluate the cardiovascular risk for the patient. Nanocardio is a 4 years for a total budget of € 1.6 million.
Partners: University of Mons (Belgium) is the project leader, and the other two operators are the University of Reims (France) and the University of Ghent (Belgium). BioWin is an associated partner of the project, together with IMEC (Leuven, Belgium), Eurasanté (Lille, France), The Institute of Electronics, Microelecrtonics and Nanotechnologies (Villeneuve d’Ascq, France) and the Centre Hospitalier Universitaire of Reims (Reims, France). Main deliverables expected (for BioWin): (1) Support and improve cross-border collaboration in research and innovation (2) Strengthen medical imaging in Wallonia, as well as scientific excellence in one of our clinical and academic assets: the cardiovascular research (3) Opportunity to create connections with new actors that could contribute to the development of BioWin and the Regional Healthcare Ecosystem.